Fidelity Investments
APVO icon

Fidelity Investments’s Aptevo Therapeutics APVO Stock Holding History

Fidelity Investments’s Portfolio APVO Stock Details APVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7
Closed -$66 – 5421
2025
Q4 		$66 Buy
+7
New +$166 ﹤0.01% 5268
2023
Q1 		– Hold
0
– -$8 – 5260
2022
Q4 		– Hold
0
– – – 5259
2022
Q3 		– Hold
0
– -$1K – 4816
2022
Q2 		– Hold
0
– – – 4662
2021
Q3 		– Hold
0
– – – 4297
2021
Q2 		– Hold
0
– – – 4201
2021
Q1 		– Hold
0
– – – 3953
2019
Q1 		– Hold
0
– -$1K – 3583
2018
Q4 		– Hold
0
– – – 3372
2018
Q3 		– Hold
0
– – – 3330
2018
Q1 		– Hold
0
– -$596K – 2661
2017
Q4 		– Hold
0
– – – 2503
2017
Q3 		– Hold
0
– – – 2371
2017
Q2 		– Hold
0
– – – 2382
2017
Q1 		– Hold
0
– – – 2394
2016
Q4 		– Hold
0
– – – 2405
2016
Q3 		– Hold
0
– – – 2571

Other funds holding APVO

GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return

Fidelity Investments's APVO Position: Q1 2026 in Review

Fidelity Investments sold out of Aptevo Therapeutics (APVO) in Q1 2026, closing a stake of 7 shares — an estimated $66 sold.

Fidelity Investments first reported a position in APVO in Q4 2025 and held it in 1 quarter. The position peaked at $66 in Q4 2025. 9 funds tracked by Wall St. Rank hold APVO as of Q1 2026.

  • Fidelity Investments reported no remaining Aptevo Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Fidelity Investments sold 7 Aptevo Therapeutics shares in Q1 2026, an estimated $66.
  • Fidelity Investments first reported a position in Aptevo Therapeutics in Q4 2025 and held it in 1 quarter.
  • Fidelity Investments's Aptevo Therapeutics position peaked at $66 in Q4 2025.
  • 9 funds tracked by Wall St. Rank held Aptevo Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.